Recombinant staphylokinase - Supergene

Drug Profile

Recombinant staphylokinase - Supergene

Alternative Names: Fortelyzin; Forteplase; Gene modified staphylokinase - Supergene; Recombinant nonimmunogenic staphylokinase - Supergene; Recombinant staphylokinase variant - Supergene

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Supergene
  • Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke
  • No development reported Myocardial infarction

Most Recent Events

  • 11 May 2017 Phase-III clinical trials in Stroke in Russia (IV) (NCT03151993)
  • 05 Apr 2017 No recent reports of development identified - Phase-III for Myocardial infarction in Russia (IV)
  • 01 Oct 2014 Phase-III clinical trials in Myocardial infarction in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top